Research from the Theertha Biopharma R&D Unit, published in Biomedicines (24 May 2023), examines the “Inhibition of LPS-Induced Inflammatory Response of Oral Mesenchymal Stem Cells in the Presence of Galectin-3.”
The study investigates how Galectin-3 influences the inflammatory response of oral mesenchymal stem cells under lipopolysaccharide (LPS) challenge — work relevant to regenerative and cell-therapy applications.
Author: Thangavelu Soundara Rajan, R&D Unit, Theertha Biopharma. Read the paper: DOI 10.3390/biomedicines11061519. More on our Publications & Patents page.